business / news / / Seeking Alpha
Biogen to buy China rights to immune disease drug for up to $850M.
Biogen will acquire exclusive Greater China rights for felzartamab from TJ Bio.
KEY POINTS
- The deal's total value could reach up to $850 million.
- Felzartamab is an antibody therapy targeting several immune-mediated disorders.
- This agreement marks Biogen's entry into the Chinese immune disease treatment market.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →